
Age and biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
Oras A Alabas, Kayleigh J Mason, Zenas Z N Yiu, Catherine H Smith, Richard B Warren, Christopher E M Griffiths, BADBIR study group
British Journal of Dermatology, ljaf017, https://doi.org/10.1093/bjd/ljaf017
Related
Uptake of tumour necrosis factor - alpha inhibitor biosimilars for psoriasis: A drug utilisation stu...
Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic ...
Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-b...
0 Comments